NEWS: JUNE 2004

-6/30/2004-

FDA approves Trinity Biotech's Uni-Gold Recombigen HIV test. To read article click here.

Archemix Corp. and Nuvelo Inc. file Investigational New Drug (IND) application to the FDA to initate Phase I clinical trials of thrombin inhibitor ARC183. To read article click here.

Introgen Therapeutics Inc. publishes in the June issue of International Immunopharmacology a review article entitled "MDA-7/IL-24 is a unique cytokine- tumor suppressor in the IL-10 Family." To read article click here.

Exelixis Inc. to cut 62 jobs (11%) of its work force. To read article click here.

CuraGen Corp. and TopoTarget A/S move histone deacetylase inhibitor PXD101 to Phase I clinical trials. To read article click here.

Merck & Co. and Alnylam Pharmaceuticals Inc. form alliance to develop and commercialize therapies for eye diseases. To read article click here.

Cephalon Inc. and Cima Laboratories Inc. to merge. To read article click here.

Amylin Pharmaceuticals Inc. and Eli Lilly and Co. file New Drug Application (NDA) to the FDA for Exenatide for Type 2 Diabetes treatment. To read article click here.

-6/29/2004-

Tularik holders to vote on acquisition by Amgen. To read article click here.

Exelixis Inc. files second IND application to the FDA for its XL999 kinase inhibitor. To read article click here.

Nymox Pharmaceutical Corp. publishes in the June edition of the Journal of Alzheimer's Disease link between neural thread protein (NTP) and impaired insulin function with brain cell death. To read article click here.

OSI Pharmaceuticals Inc.'s anticancer kinase inhibitor Tarceva™ (erlotinib HCl) accepted into the FDA's Pilot 1 Program. To read article click here.

-6/28/2004-

Press Release: Available from Genevac the Mega Series II centrifugal evaporator range set the benchmark for the most demanding large scale solvent removal applications, such as purification of library compounds and compound management. To read press release click here.

Amgen Inc.'s experimental drug GDNF for Parkinson's disease does not meet primary end point in clinical trials. To read article click here.

FDA grants Adolor Corp.'s post-surgery gastrointestinal tract compound Entereg™ (alvimopan) Fast Track status. To read article click here.

Affymetrix Inc. makes available its GeneChip® Mapping 10K 2.0 Array and the GeneChip® Mapping 100K Array Set. To read article click here.

Cell Genesys, Inc. initiates Phase II clinical trials of GVAX® lung cancer vaccine. To read article click here.

-6/25/2004-

Pfizer Inc. to buy Aventis SA's cancer drug Campto for $620 million. To read article click here.

FDA aproves Andrx Corp.'s generic version of antibiotic drug Biaxin. To read article click here.

Savient Pharmaceuticals Inc. announces pharmacoeconomic modeling. To read article click here.

Crucell N.V. discovers antibody for protection against SARS virus infection. To read article click here.

-6/24/2004-

Press Release: The MaxQ range of high performance laboratory shakers from Radleys set new standards for shaking and incubating samples. To read press release click here.

Press Release: Genetix has announced a 3-colour aQuire dual-laser microarray scanner for detection of GFP, fluorescein and a range of other fluorophores, making it an ideal and versatile system for imaging DNA, protein, cell and tissue arrays. To read press release click here.

FDA approves American Pharmaceutical Partners's Dimenhydrinate Injection for nausea, vomiting or vertigo of motion sickness. To read article click here.

Roche to invest $638.9 million in Europe plants. To read artcile click here.

-6/23/2004-

Sanofi-Synthelabo shareholders give thumbs up to the Aventis acquisition. To read article click here.

Mylan Laboratories Inc. sues the FDA. To read article click here.

Exelixis Inc. initiates Phase III clinical trials of XL119 (becatecarin) in bile duct cancer. To read article click here.

-6/22/2004-

Press Release: Genevac has announced a new 20-page technical brochure introducing its HT and Mega Series centrifugal evaporators. To read press release click here.

Sanofi-Synthelabo scheduled to take over Aventis on July 30, 2004. To read article click here.

Roche Holding AG and Kosan Biosciences Inc. stop Phase II clinical trials of KOS-862 for colorectal cancer due to unexpected toxic build-up in patients. To read article click here.

Accelrys Inc. and the US Air Force Research Laboratory Materials sign Cooperative Research and Development Agreement (CRDA) for advanced photonic materials. To read article click here.

Merck & Co. commits to pay Vertex Pharmaceuticals Inc. up to $384 million to co-develop and commercialize anticancer candidate VX-680. To read article click here.

Dynavax Technologies Corp. to initiate Phase II/III clinical trials of Engerix B® for hepatitis B (HBV). To read article click here.

FDA grants Barrier Therapeutics Inc.'s Liarozole orphan drug status for the treatment of congenital ichthyosis. To read article click here.

Chiron Corp. grants another nonexclusive license of its Hepatitis C technology to Prosetta Corp. To read article click here.

CuraGen Corp. licenses Seattle Genetics Inc.'s proprietary ADC technology. To read article click here.

-6/21/2004-

Neurochem Inc. initiates Phase III clinical trials of Alzhemed™ for the treatment of Alzheimer's Disease. To read article click here.

Titan Pharmaceuticals Inc. stops Phase IIb clinical trials of lung-cancer experimental drug Pivanex due to safety problems when combined with chemotherapy drug docetaxel. To read article click here.

-6/12/2004 to 6/20/2004-

No news due to re-installation of computer system from hard drive crash.

-6/11/2004-

Press Release: The innovative design of the Microlute™ from Porvair Sciences Ltd offers all the advantages of automated and high throughput SPE sample preparation in a convenient microplate format capable of rapidly processing 96 samples in one go repeatedly and precisely. To read press release click here.

OSI Pharmaceuticals' Phase III clinical trials of Aptosyn in combination with Taxotere for advanced non-small cell lung cancer treatment gives dissapointing results. To read article click here.

-6/10/2004-

Elan signs agreement with Eli Lilly to manufacture Lilly's antidepressant duloxetine hydrochloride capsules. To read article click here.

Par Pharmaceutical Companies Inc. completes the acquisition of Kali Laboratories Inc. for $135 million. To read article click here.

Celera Diagnostics identifies gene variant associated with increased risk for rheumatoid arthritis. To read article click here.

-6/09/2004-

Press Release: A new applications note describing the ViaCount assay and its use in counting white blood cells in unlysed whole human blood is now available from the Guava Technologies - a leading supplier of integrated cellular analysis systems for life science research. To read press release click here.

Bradley Pharmaceuticals to acquire Bioglan Pharmaceuticals for about $183 million. To read article click here.

Rigel Pharmaceuticals Inc. receives United States patents 6,737,244 and 6,740,495 for its ubiquitin ligase program. To read article click here.

ICOS Corporation and Raven Biotechnologies Inc. form antibody collaboration. To read article click here.

FDA grants orphan drug designation to Medarex's fully human anti-CTLA-4 antibody MDX-010. To read article click here.

Incara Pharmaceuticals Corporation names Dr. James D. Crapo its CEO. To read article click here.

Vertex Pharmaceuticals Inc. discloses two new compound classes for cystic fibrosis (CF). To read article click here.

Vanda Pharmaceuticals Inc. acquires worldwide rights to Titan Pharmaceuticals Inc.'s antipsychotic agent Iloperidone. To read article click here.

-6/08/2004-

GlaxoSmithKline-Vertex Pharmaceuticals Inc.'s experimental protease inhibitor 640385 shows unique mutation pattern against HIV. To read article click here.

Cellegy Pharmaceuticals Inc. receives U.S. Patent 6,747,063 entitled "Combination Therapy for Treatment of Erectile Dysfunction." To read article click here.

Kos Pharmaceuticals Inc. receives U.S. Patent 6,746,691 entitled "Intermediate Release Nicotinic Acid Compositions for Treating Hyperlipidemia Having Unique Biopharmaceutical Characteristics." To read article click here.

Vertex Pharmaceuticals Inc. initiates Phase I clinical trials of oral protease inhibitor VX-950 for the treatment of hepatitis C. To read article click here.

-6/07/2004-

Press Release: The Freedom EVOlyzer from Tecan Europe is a new Enzyme Immuno Assay (EIA) analyser offering fully automated microplate processing. To read press release click here.

Press Release: The new generation MediaClave nutrient media preparator and steriliser from INTEGRA Biosciences sets a new benchmark for operational versatility. To read press release click here.

FDA approves Ista Pharmaceuticals' Istalol™ for glaucoma treatment. To read article click here.

Genentech Inc-OSI Pharmaceuticals Inc.-Roche's experimental cancer drug Tarceva gives no advantages when compared to standard chemotherapy in patients with advanced lung cancer. To read article click here.

Genelabs Technologies Inc. to withdraw European application of Anastar™ for lupus treatment. To read article click here.

Onyx Pharmaceuticals Inc. and Bayer AG's drug BAY 43-9006 shows poor results in clinical trials for advanced pancreatic cancer. To read article click here.

ImClone Systems Inc. and Merck KGaA's cancer vaccine IMC-BEC2 did not meet primary endpoint. To read article click here.

-6/04/2004-

Press Release: Moritex has announced that it will officially launch several new products adding to its cosmetic skin counselling instrument range at CosmoProf North America in Las Vegas (18th -20th July) and Cosmeeting 2004 in Paris (France) (22nd -24th September). To read press release click here.

The European Commission approves Novo Nordisk's insulin analog Levemir® for diabetes. To read article click here.

IVAX Corporation acquires Peru-based Medco. To read article click here.

-6/03/2004-

Exelixis Inc. initiates Phase I clinical trials of receptor tyrosine kinase inhibitor XL647 for cancer indications. To read article click here.

DuPont Co. to acquire Maxygen Inc.'s Verdia Inc. for $64 million in cash. To read article click here.

Meridian Bioscience Inc. and Viral Therapeutics Inc. form alliance. To read article click here.

Panacos Pharmaceuticals Inc. and V.I. Technologies Inc. to merge. To read article click here.

Trimeris Inc. and Array BioPharma Inc. extend small molecule drug discovery inhibitors targeted towards human immunodeficiency virus (HIV). To read article click here.

Crown Partners LLC selects Tripos inc.'s Electronic Notebook™ solution for content management. To read article click here.

-6/02/2004-

Genentech's drug Avastin™ and Sanofi-Synthelabo's drug oxaliplatin™ (Eloxatin™) found to improve survival rates after colon cancer surgery. To read article click here.

CV Therapeutics Inc. to begin clinical trials of drug Ranexa™ for chronic angina treatment. To read article click here.

Iconix Pharmaceuticals Inc. and AstraZeneca form chemogenomics collaboration. To read article click here.

Oncology Inc. proposes merger with Genzyme Corporation. To read article click here.

Millennium Pharmaceuticals Inc. signs research agreement with Professor E.J. Corey (Harvard University) for novel proteasome inhibitors. To read article click here.

FDA approves Allos Therapeutics Inc.'s drug RSR13 for breast cancer. To read article click here.

-6/01/2004-

MDS Proteomics announces reorganization and repriotization. To read article click here.

FDA rejects Pozen Inc.'s experimental drug MT100 for migraine. To read article click here.

ViroLogic Inc. to acquire Aclara BioSciences Inc. for $200 million. To read article click here.

Vion Pharmaceuticals Inc. initiates Phase II clinical trials of Cloretazine™ (VNP40101M) for brain tumors. To read article click here.